X4 Pharmaceuticals, Inc.
XFORHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeX4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. At a $400.6M market cap, X4 Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Market Cap
$400.6M
Beta
0.40
P/E (TTM)
2.83
P/E (Fwd)
-5.35
EPS (TTM)
$1.43
EPS (Fwd)
$-0.76
ROE
-113.1%
ROA
-28.1%
Cash
$208.0M
Total Debt
$77.2M
Free CF
-$53.3M
52W Change
19.2%
Annual Financials
Cash vs Debt
Where XFOR stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, XFOR finished 2.02% above its 150-day moving average ($3.96) and 3.06% above its 200-day moving average ($3.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XFOR overbought or oversold?
At the August 24, 2026 close, XFOR's RSI(14) was 48.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $208.0M in cash comfortably exceeding the $77.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$53.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -113.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
XFOR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XFOR.